Current Cancer Drug Targets

Ruiwen Zhang 
Texas Tech University Health Sciences Center
1300 Coulter Drive
Amarillo, TX 79106


Stem Cell Transplantation for Chronic Myeloid Leukemia (CML): Current Indications and Perspectives

Author(s): Andrea Bacigalupo.


The introduction of tyrosine kinase inhibitors (TKIs) has reduced the indications for allogeneic stem cell transplants (SCT) in patients with chronic myeloid leukemia (CML) from 1500/year in 2000 to approximately 500/year in 2010. The recently updated indications by the European Leukemia Network include advanced-phase CML and nonresponders to second-line TKIs. Changes in transplant programs, over the past decade, have resulted in a significant reduction in transplant related mortality and this has expanded the transplant option to older patients, who may be eligible for SCT. Transplantation for blastic phase CML remains a challenge due to the high rate of post-transplant relapses. Thus, in view of this issue, several studies of TKIs after allogeneic SCT have been undertaken with encouraging results. In conclusion, allogeneic SCT remains a therapeutic option for selected patients with CML and is currently being integrated with the use of TKIs both before and after transplantation.

Keywords: allogeneic stem cell transplantation, cost-effectiveness, chronic myeloid leukemia, cure, treatment-related mortality, tyrosine kinase inhibitors.

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

Year: 2013
Page: [775 - 778]
Pages: 4
DOI: 10.2174/15680096113136660094
Price: $58